mir371 to detect minimal residual disease (mrd) and early relapse of testicular tumors
Published 1 year ago • 204 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
4:17
plasma mir371 detects mrd and early relapse of germ cell tumours
-
1:39
can the anzup surveillance recommendations detect relapse in testicular cancer?
-
2:01
mir-371a-3p as a biomarker in testicular cancer
-
1:18
climate: mir-371a-3p as a biomarker in post-orchiectomy testicular cancer
-
1:12
mir-371a-3p microrna panel alone is sufficient for diagnosis and monitoring
-
1:35
chemotherapy for early metastatic seminoma
-
6:36
understanding testicular cancer
-
0:59
benefits of a biomarker to predict sever toxicity
-
2:32
testicular cancer recurrence
-
20:51
stage i testicular cancer patterns of relapse update
-
2:00
late recurrences of nonseminomatous germ cell malignancies
-
2:39
testicular cancer: frequently asked questions brad leibovich, m.d., mayo clinic
-
5:31
serum mirna to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell
-
13:46
spotlight on testing: circulating cell free tumor dna and egfr t790m testing.
-
5:42
testicular cancer prevention and treatment | rony abou-jawde, md | mosaic life care
-
57:21
the changing face of testicular cancer management
-
0:36
check out - testicular cancer awareness
-
4:16
measuring tumor genes using cell-free dna - agbt 2015
-
3:21
outcome of men with relapses after adjuvant bep for clinical stage i nonseminoma